$39 Million Transaction: GivBux, Inc. Signs Letter of Intent to Acquire VitorganAmerica.shop Providing High-Quality Wellness Solutions to Customers Across the Americas
GivBux Inc. (OTC: GBUX) has signed a Letter of Intent to acquire VitorganAmerica.shop in a $39 million transaction. VitorganAmerica.shop is a distributor of biomolecular health products, specializing in supplements and ampoules manufactured in FDA-registered facilities across the United States and South America.
The acquisition will integrate VitorganAmerica.shop's products into GivBux's network, expanding distribution throughout the United States and Latin America. The products, developed under Dr. David Contreras's guidance, focus on regenerative treatments and biomolecular therapy. VitOrgan's technology, with a 70-year track record, combines traditional medicine with naturopathic approaches, aiming to restore organ functions through cellular regeneration.
The strategic move is expected to strengthen GivBux's product portfolio and enhance user engagement while expanding its direct-to-consumer network.
GivBux Inc. (OTC: GBUX) ha firmato una Lettera di Intenti per acquisire VitorganAmerica.shop in una transazione da 39 milioni di dollari. VitorganAmerica.shop è un distributore di prodotti per la salute biomolecolare, specializzato in integratori e fiale prodotti in strutture registrate dalla FDA negli Stati Uniti e in America del Sud.
L'acquisizione integrerà i prodotti di VitorganAmerica.shop nella rete di GivBux, espandendo la distribuzione negli Stati Uniti e in America Latina. I prodotti, sviluppati sotto la guida del Dr. David Contreras, si concentrano su trattamenti rigenerativi e terapia biomolecolare. La tecnologia di VitOrgan, con un'esperienza di 70 anni, combina la medicina tradizionale con approcci naturopatici, mirando a ripristinare le funzioni degli organi attraverso la rigenerazione cellulare.
Questa mossa strategica dovrebbe rafforzare il portafoglio prodotti di GivBux e migliorare l'interazione con gli utenti, espandendo la sua rete di vendita diretta al consumatore.
GivBux Inc. (OTC: GBUX) ha firmado una Carta de Intención para adquirir VitorganAmerica.shop en una transacción de 39 millones de dólares. VitorganAmerica.shop es un distribuidor de productos de salud biomolecular, especializado en suplementos y ampollas fabricados en instalaciones registradas por la FDA en los Estados Unidos y América del Sur.
La adquisición integrará los productos de VitorganAmerica.shop en la red de GivBux, expandiendo la distribución en los Estados Unidos y América Latina. Los productos, desarrollados bajo la guía del Dr. David Contreras, se centran en tratamientos regenerativos y terapia biomolecular. La tecnología de VitOrgan, con una trayectoria de 70 años, combina la medicina tradicional con enfoques naturopáticos, con el objetivo de restaurar las funciones de los órganos a través de la regeneración celular.
Se espera que este movimiento estratégico refuerce el portafolio de productos de GivBux y mejore la participación del usuario mientras expande su red de venta directa al consumidor.
GivBux Inc. (OTC: GBUX)는 VitorganAmerica.shop를 인수하기 위한 의향서를 체결했습니다. 이 거래는 3900만 달러 규모입니다. VitorganAmerica.shop는 미국과 남미에 있는 FDA 등록 시설에서 제조된 보충제 및 앰플을 전문으로 하는 생체분자 건강 제품의 유통업체입니다.
이번 인수로 VitorganAmerica.shop의 제품이 GivBux의 네트워크에 통합되어 미국과 라틴 아메리카 전역으로 유통이 확대될 것입니다. 이 제품들은 David Contreras 박사의 지도 하에 개발되었으며, 재생 치료 및 생체 분자 요법에 중점을 두고 있습니다. VitOrgan의 기술은 70년의 성공적인 경력을 가지고 있으며, 전통 의학과 자연 요법 접근법을 결합하여 세포 재생을 통해 장기 기능을 회복하는 것을 목표로 합니다.
이번 전략적 조치는 GivBux의 제품 포트폴리오를 강화하고 사용자 참여를 향상시키며 직판 네트워크를 확장할 것으로 기대됩니다.
GivBux Inc. (OTC: GBUX) a signé une Lettre d'Intention pour acquérir VitorganAmerica.shop dans une transaction de 39 millions de dollars. VitorganAmerica.shop est un distributeur de produits de santé biomoléculaire, spécialisé dans les compléments alimentaires et ampoules fabriqués dans des établissements enregistrés par la FDA aux États-Unis et en Amérique du Sud.
L'acquisition intégrera les produits de VitorganAmerica.shop dans le réseau de GivBux, élargissant la distribution à travers les États-Unis et l'Amérique Latine. Les produits, développés sous la direction du Dr David Contreras, se concentrent sur des traitements régénératifs et la thérapie biomoléculaire. La technologie de VitOrgan, forte de 70 ans d'expérience, combine médecine traditionnelle et approches naturopathiques, visant à restaurer les fonctions des organes par la régénération cellulaire.
Ce mouvement stratégique devrait renforcer le portefeuille de produits de GivBux et améliorer l'engagement des utilisateurs tout en élargissant son réseau de vente directe aux consommateurs.
GivBux Inc. (OTC: GBUX) hat eine Absichtserklärung unterzeichnet, um VitorganAmerica.shop in einer Transaktion im Wert von 39 Millionen Dollar zu erwerben. VitorganAmerica.shop ist ein Distributor biomolekularer Gesundheitsprodukte, der sich auf Nahrungsergänzungsmittel und Ampullen spezialisiert hat, die in von der FDA registrierten Einrichtungen in den Vereinigten Staaten und Südamerika hergestellt werden.
Die Akquisition wird die Produkte von VitorganAmerica.shop in das Netzwerk von GivBux integrieren und die Distribution in den Vereinigten Staaten und Lateinamerika erweitern. Die Produkte, die unter der Leitung von Dr. David Contreras entwickelt wurden, konzentrieren sich auf regenerative Behandlungen und biomolekulare Therapie. Die Technologie von VitOrgan, die auf einer 70-jährigen Erfolgsbilanz basiert, kombiniert traditionelle Medizin mit naturopathischen Ansätzen und zielt darauf ab, die Organfunktionen durch Zellregeneration wiederherzustellen.
Diese strategische Maßnahme wird voraussichtlich das Produktportfolio von GivBux stärken und die Nutzerinteraktion verbessern, während das Netzwerk für den Direktvertrieb an Verbraucher erweitert wird.
- Acquisition valued at $39 million expands product portfolio
- Access to FDA-registered manufacturing facilities in US and South America
- Integration with existing distribution network across Americas
- Acquisition of established 70-year-old biomolecular technology
- Transaction still in LOI phase, pending Definitive Agreement
- Significant capital commitment of $39 million
Newport Beach, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- GivBux, Inc. (OTC: GBUX) ("GivBux" or the Company"), a publicly traded Super App and charitable giving platform, announced today it has signed a Letter of Intent (LOI) to acquire VitorganAmerica.shop, a distributor of biomolecular health products. The
The terms of the acquisition will be outlined in the forthcoming Definitive Agreement.
VitorganAmerica.shop, under the guidance of renowned medical expert Dr. David Contreras, specializes in high-quality biomolecular supplements and ampoules. These products, formulated by Dr. Contreras, are manufactured in FDA-registered facilities in the United States and South America. They are widely recognized for their role in regenerative treatments and biomolecular therapy, instilling confidence in their quality and effectiveness.
“We are thrilled to join forces with GivBux to expand access to VitOrgan’s advanced biomolecular formulations,” said Dr. David Contreras, a leading authority in regenerative medicine and biomolecular therapy. “This partnership will allow us to introduce our scientifically developed products to a broader audience, supporting health and wellness worldwide.”
Umesh Tim Singh, president of GivBux Inc., expressed enthusiasm for the acquisition. "Adding VitorganAmerica.shop’s exclusive biomolecular products aligns with our mission to deliver innovative, life-enhancing solutions to our growing direct-to-consumer network," Singh said. "This strategic move strengthens our product portfolio while positioning us for business expansion and increased user engagement with GivBux."
VitOrgan’s biomolecular technology, which has been successful for over 70 years, bridges the gap between traditional medicine and naturopathic approaches. Its unique third-generation organ preparations are designed to restore organ functions by stimulating cellular regeneration.
The acquisition is expected to accelerate the growth of both companies, leveraging GivBux’s extensive marketing platform to drive sales and awareness of VitOrgan’s revolutionary health products.
About GivBux, Inc.
The GivBux Super App revolutionizes shopping by offering a user-friendly tool to make purchases swiftly and easily at over 100 national retailers, along with an expanding roster of local merchants. Users earn cash back on every purchase, a portion of which can be directed towards a charity of their choice, embodying GivBux Inc.’s commitment to "give back."
The GivBux Super App is free to use and available now at Google Play Store (Android) and the Apple App Store (IOS).. The GivBux Super App is constantly evolving and adding new enhancements and functionalities, including social networking, e-commerce, banking, messaging, food delivery and transportation.
GivBux is forging a new path in ecommerce and charitable giving and aspires to build the largest community of givers, first in the United States and eventually worldwide. For more details and regular updates, visit https://givbux.com.
About VitorganAmerica.shop
VitorganAmerica.shop is a distributor of biomolecular supplements and ampoules formulated using proprietary technology. Based on decades of research, its products support cellular regeneration and overall vitality through scientifically developed dietary solutions. For more details and regular updates, visit https://www.vitorganamerica.shop/en.
This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by GivBux, Inc. in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. The Company intends that all statements included herein, including those referring to future revenues and earnings, be subject to the "Safe Harbors" provision of the Private Securities Litigation Reform Act of 1995.
Contact:
Umesh Singh, President
Email: ir@Givbux.com
www.GivBux.com
Instagram: https://www.instagram.com/givbux/
X (formerly Twitter): https://twitter.com/givbux
FAQ
What is the value of GivBux's (GBUX) acquisition of VitorganAmerica.shop?
What products will GBUX gain through the VitorganAmerica.shop acquisition?
What markets will the GBUX-VitorganAmerica.shop merger serve?
How long has VitorganAmerica.shop's technology been in use?
When will GBUX complete the VitorganAmerica.shop acquisition?
